Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea.
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan.
Sci Rep. 2020 Nov 17;10(1):20012. doi: 10.1038/s41598-020-77075-1.
Low-grade ovarian serous carcinoma (LGSOC) has clinical features different from high-grade serous ovarian carcinoma (HGSOC) accounting for the majority of epithelial ovarian cancer. Because of its rarity, previous studies have only focused on the high-grade disease without considering the differences between the two subtypes. This study aimed to evaluate the effect of the clinical prognostic factors known for HGSOC on survival in patients with LGSOC. Based on the Federation of Gynecology and Obstetrics (FIGO) stage, progression-free survival (PFS) was markedly decreased in advanced disease compared with early disease. For stage I, patients with stage IC had poorer survival than those with stage IA and IB regardless of the number of cycles of adjuvant chemotherapy. For advanced disease, no gross residual disease after primary cytoreductive surgery was significantly associated with longer PFS when compared with gross residual disease. In multivariate analysis for PFS and overall survival (OS), age, preoperative CA-125, time interval from surgery to chemotherapy, and the number of cycles of adjuvant chemotherapy were not associated with prognosis. Complete cytoreduction was the only independent prognostic factor for PFS (HR 2.45, p = 0.045). Our study revealed that the known prognostic factors in HGSOC did not show any effect on the survival in LGSOC except for FIGO stage and complete cytoreduction.
低级别浆液性卵巢癌 (LGSOC) 的临床特征与大多数上皮性卵巢癌的高级别浆液性卵巢癌 (HGSOC) 不同。由于其罕见性，以前的研究仅集中在高级别疾病上，而没有考虑两种亚型之间的差异。本研究旨在评估已知与 HGSOC 相关的临床预后因素对 LGSOC 患者生存的影响。根据妇产科联合会 (FIGO) 分期，与早期疾病相比，晚期疾病的无进展生存期 (PFS) 明显降低。对于 I 期，无论辅助化疗周期数如何，与 IA 和 IB 期相比，IC 期患者的生存更差。对于晚期疾病，与大残留疾病相比，原发细胞减灭术后无明显残留疾病与更长的 PFS 显著相关。在 PFS 和总生存期 (OS) 的多因素分析中，年龄、术前 CA-125、手术至化疗的时间间隔和辅助化疗周期数与预后无关。完全肿瘤减灭术是 PFS 的唯一独立预后因素 (HR 2.45，p = 0.045)。我们的研究表明，除了 FIGO 分期和完全肿瘤减灭术外，HGSOC 中已知的预后因素对 LGSOC 的生存没有任何影响。
